Search Results
Search for other papers by Walid Zeyghami in
Google Scholar
PubMed
Search for other papers by Marie-Louise Uhre Hansen in
Google Scholar
PubMed
Search for other papers by Kathrine Kronberg Jakobsen in
Google Scholar
PubMed
Search for other papers by Christian Groenhøj in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Christian von Buchwald in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
released from the primary tumors such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA) ( Fig. 1 ). Several techniques have been developed to detect liquid biopsies ( Palmirotta et al. 2018 , Lone et al. 2022 ). The increased release of cfDNA
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Erika Maria Grossrubatscher in
Google Scholar
PubMed
Search for other papers by Elia Guadagno in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
performed in cancer fields different from NENs. Aim The aim of this review is to summarize the available data on two new putative prognostic biomarkers for NENs, such as circulating tumors cells (CTCs) and microRNAs (miRNAs). Methods Among
Search for other papers by Nely Díaz-Mejía in
Google Scholar
PubMed
Search for other papers by David García-Illescas in
Google Scholar
PubMed
Search for other papers by Rafael Morales-Barrera in
Google Scholar
PubMed
Search for other papers by Cristina Suarez in
Google Scholar
PubMed
Search for other papers by Jacques Planas in
Google Scholar
PubMed
Search for other papers by Xavier Maldonado in
Google Scholar
PubMed
Search for other papers by Joan Carles in
Google Scholar
PubMed
Search for other papers by Joaquin Mateo in
Google Scholar
PubMed
evaluated the response to olaparib among 49 men with mCRPC, defining response as either a radiological response according to RECIST, a PSA response >50% and/or a confirmed circulating tumor cells (CTC) count conversion from high to low counts. Overall, 33
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Mark Daniel in
Google Scholar
PubMed
Search for other papers by Todd P Knutson in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Jamie M Sperger in
Google Scholar
PubMed
Search for other papers by Yingming Li in
Google Scholar
PubMed
Search for other papers by Anupama Singh in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Charlotte N Stahlfeld in
Google Scholar
PubMed
Search for other papers by Courtney Passow in
Google Scholar
PubMed
Search for other papers by Benjamin Auch in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Joshua M Lang in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Scott M Dehm in
Google Scholar
PubMed
are challenging and a high burden for patients. As a result, assessing CRPC genomic alterations via blood-based 'liquid biopsy' is an attractive alternative. One common liquid biopsy approach involves the examination of circulating tumor cells (CTCs
Search for other papers by Alexa Childs in
Google Scholar
PubMed
Search for other papers by Christopher D Steele in
Google Scholar
PubMed
Search for other papers by Clare Vesely in
Google Scholar
PubMed
Search for other papers by Francesca M Rizzo in
Google Scholar
PubMed
Search for other papers by Leah Ensell in
Google Scholar
PubMed
Search for other papers by Helen Lowe in
Google Scholar
PubMed
Search for other papers by Pawan Dhami in
Google Scholar
PubMed
Search for other papers by Heli Vaikkinen in
Google Scholar
PubMed
Search for other papers by Tu Vinh Luong in
Google Scholar
PubMed
Search for other papers by Lucia Conde in
Google Scholar
PubMed
Search for other papers by Javier Herrero in
Google Scholar
PubMed
Search for other papers by Martyn Caplin in
Google Scholar
PubMed
Search for other papers by Christos Toumpanakis in
Google Scholar
PubMed
Department of Oncology, Royal Free London NHS Foundation Trust, London, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
Search for other papers by John A Hartley in
Google Scholar
PubMed
Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, UK
Search for other papers by Nischalan Pillay in
Google Scholar
PubMed
Department of Oncology, Royal Free London NHS Foundation Trust, London, UK
Search for other papers by Tim Meyer in
Google Scholar
PubMed
. Furthermore, characterization of single-circulating tumor cells (CTCs) as part of a minimally invasive 'liquid biopsy' provides an opportunity to explore tumor biology and identify therapeutic targets. The first clinical applications of CTCs focused on
Search for other papers by Courtney A Dreyer in
Google Scholar
PubMed
Search for other papers by Kacey VanderVorst in
Google Scholar
PubMed
Search for other papers by Savannah Free in
Google Scholar
PubMed
Search for other papers by Ashley Rowson-Hodel in
Google Scholar
PubMed
Search for other papers by Kermit L Carraway III in
Google Scholar
PubMed
), and association with cells in circulation ( Lambert et al. 2017 ). Important intermediaries of the distant metastatic cascade are circulating tumor cells (CTCs), which exit primary tumors as single cells or clusters and travel to distant sites to
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Laura Gerard in
Google Scholar
PubMed
Search for other papers by Céline Patte in
Google Scholar
PubMed
Search for other papers by Laurence Chardon in
Google Scholar
PubMed
Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Léa Payen in
Google Scholar
PubMed
Search for other papers by Marion Allio in
Google Scholar
PubMed
Search for other papers by Claire Marx in
Google Scholar
PubMed
Search for other papers by Hugo Clermidy in
Google Scholar
PubMed
Search for other papers by Alice Durand in
Google Scholar
PubMed
Search for other papers by Patrick Mehlen in
Google Scholar
PubMed
Search for other papers by Julien Bollard in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Colette Roche in
Google Scholar
PubMed
Search for other papers by Benjamin Gibert in
Google Scholar
PubMed
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
have emerged as a non-invasive and repeatable alternative during disease course. Circulating tumour cells (CTCs) are tumour cells that have shed from the primary tumour and extravasated into the bloodstream ( Garcia et al. 2019 , Mandair et al
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
treatment and response to first-line cisplatin–etoposide combination, date of FOLFOX initiation, schedules of chemotherapy, number of cycles administered, toxicity according to the National Cancer Institute Common Terminology Criteria (NCI-CTC) v.4.0, dose
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by D Mandair in
Google Scholar
PubMed
Search for other papers by C Vesely in
Google Scholar
PubMed
Search for other papers by L Ensell in
Google Scholar
PubMed
Search for other papers by H Lowe in
Google Scholar
PubMed
Search for other papers by V Spanswick in
Google Scholar
PubMed
Search for other papers by J A Hartley in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by T Meyer in
Google Scholar
PubMed
Dear Editor, Circulating tumour cells (CTCs) have been hypothesised to be mediators of metastases ( Fidler et al . 2003 ) but with numbers as low as 1/10 7 white cells ( Alunni-Fabbroni & Sandri 2010 ), their utility as biomarkers has been
Molecular Biology (TERRA), University of Liege, Gembloux, Belgium
Search for other papers by Sathya Neelature Sriramareddy in
Google Scholar
PubMed
Search for other papers by Etienne Hamoir in
Google Scholar
PubMed
Search for other papers by Marcela Chavez in
Google Scholar
PubMed
Search for other papers by Renaud Louis in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Molecular Biology (TERRA), University of Liege, Gembloux, Belgium
Search for other papers by Luc Willems in
Google Scholar
PubMed
despite metastasis of rare tumor cells in thyroidectomized patients. In this context, we designed a sensitive and specific technique to identify calcitonin-positive circulating tumor cells (CTC) in medullary thyroid carcinoma. We demonstrate that